Novembre Dicembre 2016 - In depth review

The influence of phosphate, calcium and magnesium on matrix Gla-protein and vascular calcification: a systematic review


Vitamin K-dependent matrix Gla protein (MGP) is a key inhibitor of vascular calcification (VC). MGP is synthesized by chondrocytes and vascular smooth muscle cells (VSMC) and the absence or inactivity of MGP results in excessive calcification of both growth plate and vasculature. Apart from its vitamin K dependency little is known about other factors that influence MGP metabolism. Phosphate, calcium and magnesium are involved in bone mineralization and play an important role in VC. In this review we provide a summary of the effect of phosphate, calcium, and magnesium on MGP metabolism. Elevated phosphate and calcium levels promote VC, in part by increasing the release of matrix vesicles (MV) that under the influence of calcium and phosphate become calcification competent. Phosphate and calcium simultaneously induce an upregulation of MGP protein and gene expression, which possibly inhibits calcification. Elevated phosphate levels did not change MGP protein levels in MV. On the contrary, elevated calcium concentrations caused a decrease of MGPloading in MV, which might in part explainthe calcifying effects of MV. Magnesium is a known inhibitor of VC. However, magnesium has been shown to have an inhibitory effect on MGP synthesis induced through downregulation of the calcium-sensing receptor and hereby causing a decrease in calcium induced MGP upregulation. There might also be stimulatory effect of magnesium on MGP in which the TRPM7 channel is involved. In conclusion there is a clear interaction between MGP and phosphate, calcium and magnesium. The upregulation of MGP by phosphate and calcium might be a cellular response that possibly results in the mitigation of VC.

Key words: Carboxylation, ckd-mbd, magnesium, MGP, Minerals, vascular calcification



Cardiovascular events account for 50% of all death in patients with end stage renal disease[1] (full text). This increased cardiovascular risk is partly caused by a process known as vascular calcification (VC). VC is characterized by increased calcium salt depositions in the arteries leading to arterial stiffness [1] (full text) [2] (full text). VC is a complex process that is similar to bone formation and involves transdifferentiation of vascular smooth muscle cells (VSMCs) into osteoblast-like cells [3] (full text) [4] (full text). The transdifferentiation of VSMC results from an imbalance between pro-osteogenic factors and osteogenesis inhibitors [5] (full text). In addition, the precipitation of calcium and phosphate in the form of hydroxyapatite crystalsis an important component of VC. The precipitation of hydroxyapatite is initially mediated by small, membranous vesicles that form a nidus for calcification and contain minerals and substances that fuel this process. These vesicles are termed matrix vesicles (MV) and are released from the cell membrane of resident cells in the vessel wall [6].

Matrix γ-carboxy-glutamate (Gla) protein (MGP) is a protein secreted by chondrocytes as well as VSMC and is a key inhibitor of VC [7] [8] [9] (full text). Knock-out mice lacking MGP develop extensive calcification in arteries and cartilages and die within six to eight weeks after birth as a result of blood-vessel rupture [7]. In humans, mutations in the gene encoding MGP result in the Keutel syndrome, a rare disorder characterized by abnormal calcification of soft tissues [10] [11]. Several mechanisms by which MGP inhibits calcification have been postulated. Firstly, it has been suggested that MGP binds hydroxyapatite crystals thereby shielding nucleation sites for mineral growth. Thus, MGP might act as a competitor to hydroxyapatite precipitation in VC[12] (full text) [13] (full text). Secondly, MGP can bind and inactivate bone morphogenetic protein-2 (BMP-2). BMP-2 is an osteogenic growth factor, found to be active in VSMCs [14]. Besides that, MGP-null mice demonstrated an upregulated expression of the bone-specific transcription factor cbf1a/Runx2 and the osteogenic protein osteopontin. The upregulation of these genes is associated with transdifferentiation of VSMCs into osteoblast-like cells [15] (full text).

Before MGP can exert its calcification inhibitory effects, it has to undergo two posttranslational modifications: γ-glutamate carboxylation and serine phosphorylation (illustrated in Figure 1). Carboxylated and phosphorylated MGP is regarded as the active form of MGP [16] (full text) [17] (full text). The ratio of active MGP compared to inactive MGP in plasma is unknown. Most ELISA-based detection strategies used so far do not differentiate between all different MGP conformations (Figure 1).

The carboxylation of MGP is entirely dependent on the presence of its cofactor vitamin K [17] (full text). Little is known about factors involved in the phosphorylation of MGP. Phosphate, calcium and magnesium are major components of cartilage and bone [18]. In addition, these ions play an important role in the pathogenesis of VC. As a result, many studies focused on the role of phosphate, calcium and magnesium in VC [19] [20] (full text) [21] (full text) [22] [23]. However, only a limited number of studies describe the direct interaction of these ions with MGP. Recent literature suggests interaction between MGP and these ions, however data are conflicting. This article aims to provide an overarching conceptual framework of the complex interaction between MGP, phosphate, calcium and magnesium.


We identified studies from the bibliographic databases of PubMed between the 1st of December 2014 until the 1st of January 2015, using search terms: ‘phosphate AND matrix Gla protein’, ‘calcium AND matrix Gla protein’, ‘magnesium AND matrix Gla protein’, AND ‘interaction’ AND ‘stimulation’. We found a total number of 556 articles. All studies, either in vitro or in vivo, that focused on the direct interaction of phosphate and/or calcium and/or magnesium with MGP were included. Based on these criteria, 11 studies were classified as eligible; all of which were in vitro studies.


In CKD hyperphosphatemia is a common complication. There is compelling evidence that elevated phosphate levels correlate with VC and result in a higher cardiovascular mortality in CKD patients [24] (full text) [25] (full text) [26] (full text) [27] (full text). The mechanisms by which phosphate induces VC are, however not fully understood. It is known that the presence of high levels of phosphate accelerate the precipitation of calcium and phosphate in the form of hydroxyapatite [26] (full text). In mouse VSMCs, elevated phosphate levels stimulate the expression of osterix, an osteoblastic transcription factor. Osterix is an essential factor in the formation of calcification prone MV [28] (full text). Under physiological conditions these MVdo not calcify since they contain calcification inhibitors such as MGP and Fetuin-A [26] (full text). However, an elevated phosphate level results in an increased release of MV that are mineralization competent and might form a nidus for hydroxyapatite precipitation [26] (full text).

Four studies reported that high phosphate levels increased MGP levels (Table 1) [5] (full text); [29][30] (full text) [31]. One study found no effect of phosphate on MGP levels [32] (full text). The effect of phosphate on MGP was first investigated in an in vitro model using the ATDC5 cell line. ATDC5 cells are derived from teratocarcinoma that differentiate into chondrocytes [33]. An elevated phosphate level induced a statistically significant 6-fold increase in MGP mRNA expression as compared to control [29]. There are however, two important limitations to these studies. Firstly, the concentration of phosphate was unphysiologically high, and secondly no data are presented on the posttranslational modification of MGP, which dictates its activity.

Hyperphosphatemia induces upregulation of the ERK1/2-Fra-1 pathway, which was shown to be essential for upregulation of MGP [30] (full text). The ERK1/2-Fra-1 pathway consists of the ERK1/2 cascade, a member of the MAPK family that communicates extracellular signals to the nucleus, which results in transcription of proteins [34]. Blocking ERK1/2 signal transduction using U0126, a widely used inhibitor of MEK1/2, the upstream kinases of ERK1/2, suppressed Pi-stimulated induction of MGP at both mRNA and protein level [30] (full text). Additionally, Fra-1 expression is stimulated by phosphate [30] (full text). Fra-1 is a key regulator of MGP expression, since overexpression of Fra-1 increased MGP expression in primary osteoblasts [35] (full text). Blocking ERK1/2 activation suppressed the stimulating effect of phosphate on Fra-1. Besides that, ERK1/2 activity also prevents FRA-1 from degradation. These data strongly suggest that phosphate stimulates MGP by activating Fra-1 through the ERK1/2 pathway [30] (full text). Additionally PiT-1, an active transporter of phosphate into VSMCs [36] (full text), may also play a role in the ERK1/2 pathway. Elevated Pi-induced signaling via ERK1/2 phosphorylation was abrogated in PiT-1 deficient VSMCs [37].

One recent study focused on MV isolated from VSMC that were treated with elevated phosphate. The amount of MGP in MV remained unchanged compared with MV originating from VSMC that were not treated with phosphate [32] (full text). This is not in line with results that phosphate upregulates total MGP in VSMCs. Moreover, it was suggested that phosphate reduces the affinity of MGP for hydroxyapatite [38].

In summary, phosphate stimulates total MGP and MGP transcription through the ERK1/2-Fra-1 pathway. However the amount of MGP in MV is not affected by elevated phosphate levels. In addition phosphate may limit the affinity of MGP to hydroxyapatite crystals. This suggests that in spite of the overall effects of phosphate on VC, phosphate leads to higher levels of MGP and MGP transcription, possibly resulting in some mitigation of VC.


Calcium is an abundant ion that plays an important role in the pathogenesis of VC. Both in vivo and in vitro studies showed a correlation between calcification and high calcium levels. This effect is both independent and synergistic with elevated phosphate levels [31] [39]. Multiple mechanisms are responsible for the calcifying effects of calcium ions, including an increased production of mineralization competent MV [26] (full text). If both high phosphate and calcium are present, calcification effects are strongly enhanced [21] (full text) [26] (full text).

However, despite the calcifying effects of calcium, an elevated calcium level can also induce an increase in both MGP transcription and MGP protein level. These effects are described in four studies summarized in Table 1. In three studies it was shown that calcium increased the level of MGP [31] [40] [41], while one study in turn found a decrease in MGP [32] (full text). In one study, it was shown in a MC3T3-E1 cell line that both calcium and phosphate are required to induce a rise in MGP. In comparison to the studies describing the effects of phosphate on MGP metabolism, the concentrations for calcium appear unphysiologically high. However, local tissue calcium levels can exceed plasma concentrations, possibly due to local apoptosis and therefore data from these in vitro studies might still be applicable and translated to the clinical situations [21] (full text).

The interaction between calcium and phosphate ions is probably based on the formation of precipitates that stimulate ERK1/2 phosphorylation [31]. As previously mentioned, phosphorylated ERK1/2results in an increase in both protein and mRNA MGP levels. In human aortic VSMC the phosphorylation of ERK1/2 can be mediated through the calcium-sensing receptor (CaSR) [42] (full text). Calcium in rat VSMC stimulates the upregulation of MGP through a pathway that might involve a receptor, that is functionally related to the CaSR. CaSR-agonists induce a significant stimulation of MGP transcription in rat aorta VSMC. However, when rtPCR was carried out on total rat mRNA with a known CaSR primer, the CaSR was not found in this cell line. This suggests the presence of another receptor that is functionally related, but molecularly distinct from the CaSR [41]. However, more recent studies using a more selective calcimimetic do suggest that the CaSR is involved [43]. Calcium does not only increase the amount of MGP, but can even influence the effectiveness of MGP in preventing VC. In the presence of high calcium, MGP shows an increased affinity for hydroxyapatite. It is suggested that calcium induces a conformational change of MGP that promotes MGP-hydroxyapatite binding [38].

In contrast with these data, one study focused on MGP in MV released from VSMC. Under pathologic conditions MV can promote calcification. It was found that when human aortic VSMC are treated with calcium, the amount of MGP in MV initially rises, but after 48 hours treatment MGP diminishes [32] (full text).

In summary, the majority of these data support the hypothesis that MGP is upregulated in response to elevated calcium levels. This might imply an inherent protective mechanism in the formation of VC by high levels of calcium through the up regulation and conformation of MGP. However, in response to elevated calcium levels, the amount of MGP in MV decreased. The overall impact of calcium-mediated effects on MGP metabolism on calcification is not fully elucidated and more research is needed.


Magnesium is widely known as an inhibitor of VC both in vitro and in vivo [5] (full text) [44]. Magnesium does not only prevent, but may even decrease already existing VC [45] (full text). Some in vitro studies found that its inhibiting function is exerted in the presence of phosphate or calcium [5] (full text) [40] [45] (full text) [46] (full text). The mechanisms by which magnesium prevents VC are not fully established. Among others effects, magnesium directly prevents apatite crystallization in vitro [47]. Also, magnesium inhibits the Wnt/β-catenin signaling pathway, a pathway involved in VC [45] (full text). Besides that, together with other ions, magnesium directly affects MGP expression, as discussed below.

The interaction between magnesium and MGP was studied in five studies, summarized in Table 1. In two studies magnesium was found to reduce the level of MGP [5] (full text) [40] whereas in three other studies it increased the level of MGP [45] (full text) [46] (full text) [48] (full text). In a recent study that investigated human aortic VSMC with phosphate-induced calcification, higher concentrations of magnesium decreased the level of MGP. Magnesium had no effect on MGP levels in the absence of phosphate [5] (full text). Another study investigated an ATDC5 cell line treated with both calcium and magnesium. In the presence of magnesium, calcium-induced elevated MGP levels declined. This study reported that calcium increases MGP through the CaSR and that magnesium downregulates the expression of the CaSR and thereby causes a decrease in calcium induced MGP [40]. Finally, magnesium was found to reduce the affinity of MGP for hydroxyapatite, by competing with MGP for binding sites. This competition in binding site might be explained either by magnesium-hydroxyapatite binding or magnesium-MGP binding. Magnesium might also affect the conformation of MGP [38].

However, other recent studies show that magnesium increases the level of MGP. In calcifying VSMC MGP was increased by magnesium in the absence but also in the presence of other ions. These studies were performed using human, bovine or rat VSMC [45] (full text) [46] (full text) [48] (full text). Incubating calcifying bovine VSMC with β-glycerophosphate, a calcification medium, led to an 86% decrease of MGP secretion. When magnesium was added, MGP first normalized and after the addition of up to 3mM magnesium, MGP even increased to 68% above baseline values[48] (full text). It was found that when the magnesium channel TRPM7, responsible for magnesium entry into the cell was blocked, the induced increase in MGP was reversed [46] (full text).

In summary, whether magnesium upregulates or downregulates MGP remains controversial. There seem to be two pathways for the interaction between magnesium and MGP: an inhibitory effect possibly through the downregulation of the expression of the CaSR and a stimulatory effect in which cellular entry across the TRPM7 channel is involved. The net effect of magnesium on VC is inhibitory, but whether this is despite of or due to the interaction with MGP, still needs to be elucidated. An overview of the interactions of phosphate, calcium and magnesium on both VC and MGP is provided in Figure 2.


While phosphate and calcium are both potential inducers of VC, magnesium is generally considered to be protective against VC. In the presence of phosphate and calcium an upregulation of MGP is observed. However in MV elevated calcium concentration caused a decrease in MGP whereas an elevated phosphate level had no effect on MGP. The effect of magnesium on MGP remains controversial.

Data on the interaction between MGP and calcium and/or phosphate were consistent, usually pointing to increased production of MGP by these minerals, except for one study by Kapustin et al. [32] (full text) In that study MGP was investigated in mineralization competent MV in particular. They found that MGP was significantly reduced in MV released from VSMC treated with calcium and remained unchanged after treatment with phosphate. These contradictory results could possibly be explained by the fact that Kapustin and colleagues focused on MGP in MV instead of total MGP including intracellular MGP.

MGP in MV was shown to represent at least the phosphorylated form of MGP [49] (full text). MGP is a highly insoluble protein that is carried intracellular in vesicular structures which are probably precursors of MV. This fraction contains acidic MGP, which was identified as the phosphorylated form of MGP. This phosphorylated form of MGP was undetectable in the cytosolic fraction of VSMC [49] (full text). Although the carboxylation status of the microsomal MGP is unknown, this might suggest that Kapustin and colleagues detected activated MGP, since this study focused on MGP in MV, in contrast to other studies. Although future research should confirm this hypothesis, this might indicate that calcium and phosphate increase the level of inactive MGP, but reduce the physiologically active form of MGP, present in MV. Furthermore clinical studies showed that circulating uncarboxylated and dephosphorylated MGP increased progressively in a CKD setting and high levels of these inactive metabolites were associated with the severity calcification [9] (full text). Hence, an increase in MGP in the presence of calcification factors does not necessarily indicate an increase in activated MGP and an effective protective mechanism.

Magnesium has a protective effect on VC, but the data on the interaction between magnesium and MGP are contradictory. All reviewed articles that involved magnesium and MGP, focused on total MGP protein or MGP transcription. There was no difference found in methodology, such as: used ion levels, cell lines or MGP detection strategies that could explain the differences in outcomes. We did not find studies with a specific focus on MGP in MV.

A suggested pathway involved in the inhibition of MGP by magnesium is the CaSR. Indeed the presence of CaSR was found in ATDC5 cells and its expression was inhibited by magnesium, limiting upregulation of MGP [40]. However in other studies using rat aorta VSMC or the MC3T3-E1 cell line, the CaSR was not detected [31] [41]. In human aorta VSMC, however, the CaSR protein was detectable [42] (full text). Nevertheless, whether magnesium induces inhibition of MGP through the suppression of the CaSR remains questionable. Future research should elucidate if the CaSR plays a role in MGP regulation in CKD patients.

Future research should focus on the interaction of MGP with all ions together and should differentiate between different forms of MGP, in which recently introduced antibodies that detect specific forms of MGP [22] could be of use. A better understanding of factors that influence MGP, could lead to new insights for future therapies in VC. One such example is the effect of calcimimetics, CaSR agonist that are often used in CKD patients in order to control secondary hyperparathyroidism. One recent clinical trial showed that calcimimetics can prevent VC in ESRD patients and several in vitro studies showed that this effect is possibly achieved by the upregulation of MGP [43] [50] [51] (full text). Another example is the suggestion that phosphate binders may increase, instead of reduce the risk of VC [52] (full text). Although it is suggested this is due to the alleged detrimental effects of the calcium content of binders used, this is still unproven, and the effects of these binders on MGP unknown [52] (full text). This review should be a call for more in-depth research into the complex mechanisms that underlie vascular calcifications, and the influence of minerals on the cellular protective responses. Especially the role of MGP is far from settled, while being a potent protein to protect the vessel walls.

An important limitation of the articles reviewed, is that all studies used strategies that detected either MGP transcription or total MGP. As previously described, MGP can only exert its inhibiting function after post-translational modifications [16] (full text) [53] (full text). Therefore, the detection of MGP transcription does not necessarily reflect active MGP, but the production of its precursor. Antibodies used in protein detection do often not differentiate between active or inactive MGP either. It was also found that antibodies used in ELISA, not only target all forms of MGP, but cross-react with other MGP-like antigens, such as fetuin-A [49] (full text). Therefore, it is uncertain if the results obtained by the reviewed studies indicate biologically effective interactions. Furthermore, in this article we focused on the interaction between MGP, phosphate calcium and magnesium in VSMC, chondrocyte and osteoblast cell lines. Although we did not find clear differences between MGP interactions in different cell lines, this could account for some bias in our review. Some of the differences between studies could be explained by the non-physiological conditions that are inherent of in vitro models. In turn, it is possible that under pathological conditions like severe hyperphosphatemia, the physiological protection from MGP in VSMC is lost, and some models detect this abnormal response.


Calcium and phosphate induce VC, but might simultaneously limit their calcifying effects by the upregulation of MGP. However in MV elevated calcium concentrations caused a decrease in MGP and an elevated phosphate level had no effect on MGP. Magnesium prevents vascular calcification, but its effect on MGP remains unclear. An inhibitory effect of magnesium is possibly induced through the CaSR and a there might also be stimulatory effect in which the TRPM7 channel is involved. More knowledge is required to fully understand the underlying mechanisms of the interactions and possible clinical implications.


[1] London GM, Guérin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association 2003 Sep;18(9):1731-40 (full text)

[2] Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. The New England journal of medicine 2000 May 18;342(20):1478-83 (full text)

[3] Abedin M, Tintut Y, Demer LL et al. Vascular calcification: mechanisms and clinical ramifications. Arteriosclerosis, thrombosis, and vascular biology 2004 Jul;24(7):1161-70 (full text)

[4] Duer MJ, Friscić T, Proudfoot D et al. Mineral surface in calcified plaque is like that of bone: further evidence for regulated mineralization. Arteriosclerosis, thrombosis, and vascular biology 2008 Nov;28(11):2030-4 (full text)

[5] Louvet L, Büchel J, Steppan S et al. Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association 2013 Apr;28(4):869-78 (full text)

[6] Anderson HC Matrix vesicles and calcification. Current rheumatology reports 2003 Jun;5(3):222-6

[7] Luo G, Ducy P, McKee MD et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997 Mar 6;386(6620):78-81

[8] Price PA, Urist MR, Otawara Y et al. Matrix Gla protein, a new gamma-carboxyglutamic acid-containing protein which is associated with the organic matrix of bone. Biochemical and biophysical research communications 1983 Dec 28;117(3):765-71

[9] Schurgers LJ, Barreto DV, Barreto FC et al. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clinical journal of the American Society of Nephrology : CJASN 2010 Apr;5(4):568-75 (full text)

[10] Hur DJ, Raymond GV, Kahler SG et al. A novel MGP mutation in a consanguineous family: review of the clinical and molecular characteristics of Keutel syndrome. American journal of medical genetics. Part A 2005 May 15;135(1):36-40

[11] Munroe PB, Olgunturk RO, Fryns JP et al. Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome. Nature genetics 1999 Jan;21(1):142-4

[12] Yagami K, Suh JY, Enomoto-Iwamoto M et al. Matrix GLA protein is a developmental regulator of chondrocyte mineralization and, when constitutively expressed, blocks endochondral and intramembranous ossification in the limb. The Journal of cell biology 1999 Nov 29;147(5):1097-108 (full text)

[13] Lomashvili KA, Wang X, Wallin R et al. Matrix Gla protein metabolism in vascular smooth muscle and role in uremic vascular calcification. The Journal of biological chemistry 2011 Aug 19;286(33):28715-22 (full text)

[14] Wallin R, Cain D, Hutson SM et al. Modulation of the binding of matrix Gla protein (MGP) to bone morphogenetic protein-2 (BMP-2). Thrombosis and haemostasis 2000 Dec;84(6):1039-44

[15] Steitz SA, Speer MY, Curinga G et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circulation research 2001 Dec 7;89(12):1147-54 (full text)

[16] Schurgers LJ, Spronk HM, Skepper JN et al. Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification. Journal of thrombosis and haemostasis : JTH 2007 Dec;5(12):2503-11 (full text)

[17] Furie B, Bouchard BA, Furie BC et al. Vitamin K-dependent biosynthesis of gamma-carboxyglutamic acid. Blood 1999 Mar 15;93(6):1798-808 (full text)

[18] Green J The physicochemical structure of bone: cellular and noncellular elements. Mineral and electrolyte metabolism 1994;20(1-2):7-15

[19] Evrard S, Delanaye P, Kamel S et al. Vascular calcification: from pathophysiology to biomarkers. Clinica chimica acta; international journal of clinical chemistry 2015 Jan 1;438:401-14

[20] Mathew S, Tustison KS, Sugatani T et al. The mechanism of phosphorus as a cardiovascular risk factor in CKD. Journal of the American Society of Nephrology : JASN 2008 Jun;19(6):1092-105 (full text)

[21] Shanahan CM, Crouthamel MH, Kapustin A et al. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circulation research 2011 Sep 2;109(6):697-711 (full text)

[22] Schurgers LJ, Cranenburg EC, Vermeer C et al. Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Thrombosis and haemostasis 2008 Oct;100(4):593-603

[23] Schurgers LJ, Uitto J, Reutelingsperger CP et al. Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization. Trends in molecular medicine 2013 Apr;19(4):217-26

[24] Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. Journal of the American Society of Nephrology : JASN 2005 Feb;16(2):520-8 (full text)

[25] Jono S, McKee MD, Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification. Circulation research 2000 Sep 29;87(7):E10-7 (full text)

[26] Reynolds JL, Joannides AJ, Skepper JN et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. Journal of the American Society of Nephrology : JASN 2004 Nov;15(11):2857-67 (full text)

[27] Davies MR, Lund RJ, Mathew S et al. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. Journal of the American Society of Nephrology : JASN 2005 Apr;16(4):917-28 (full text)

[28] Nishimura R, Wakabayashi M, Hata K et al. Osterix regulates calcification and degradation of chondrogenic matrices through matrix metalloproteinase 13 (MMP13) expression in association with transcription factor Runx2 during endochondral ossification. The Journal of biological chemistry 2012 Sep 28;287(40):33179-90 (full text)

[29] Julien M, Magne D, Masson M et al. Phosphate stimulates matrix Gla protein expression in chondrocytes through the extracellular signal regulated kinase signaling pathway. Endocrinology 2007 Feb;148(2):530-7

[30] Julien M, Khoshniat S, Lacreusette A et al. Phosphate-dependent regulation of MGP in osteoblasts: role of ERK1/2 and Fra-1. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2009 Nov;24(11):1856-68 (full text)

[31] Khoshniat S, Bourgine A, Julien M et al. Phosphate-dependent stimulation of MGP and OPN expression in osteoblasts via the ERK1/2 pathway is modulated by calcium. Bone 2011 Apr 1;48(4):894-902

[32] Kapustin AN, Davies JD, Reynolds JL et al. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circulation research 2011 Jun 24;109(1):e1-12 (full text)

[33] Yao Y, Wang Y ATDC5: an excellent in vitro model cell line for skeletal development. Journal of cellular biochemistry 2013 Jun;114(6):1223-9

[34] Sugden PH, Clerk A Regulation of the ERK subgroup of MAP kinase cascades through G protein-coupled receptors. Cellular signalling 1997 Aug;9(5):337-51

[35] Eferl R, Hoebertz A, Schilling AF et al. The Fos-related antigen Fra-1 is an activator of bone matrix formation. The EMBO journal 2004 Jul 21;23(14):2789-99 (full text)

[36] Crouthamel MH, Lau WL, Leaf EM et al. Sodium-dependent phosphate cotransporters and phosphate-induced calcification of vascular smooth muscle cells: redundant roles for PiT-1 and PiT-2. Arteriosclerosis, thrombosis, and vascular biology 2013 Nov;33(11):2625-32 (full text)

[37] Chavkin NW, Chia JJ, Crouthamel MH et al. Phosphate uptake-independent signaling functions of the type III sodium-dependent phosphate transporter, PiT-1, in vascular smooth muscle cells. Experimental cell research 2015 Apr 10;333(1):39-48

[38] Roy ME, Nishimoto SK Matrix Gla protein binding to hydroxyapatite is dependent on the ionic environment: calcium enhances binding affinity but phosphate and magnesium decrease affinity. Bone 2002 Aug;31(2):296-302

[39] Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. American journal of kidney diseases : the official journal of the National Kidney Foundation 1998 Apr;31(4):607-17

[40] Nakatani S, Mano H, Ryanghyok IM et al. Excess magnesium inhibits excess calcium-induced matrix-mineralization and production of matrix gla protein (MGP) by ATDC5 cells. Biochemical and biophysical research communications 2006 Sep 29;348(3):1157-62

[41] Farzaneh-Far A, Proudfoot D, Weissberg PL et al. Matrix gla protein is regulated by a mechanism functionally related to the calcium-sensing receptor. Biochemical and biophysical research communications 2000 Nov 2;277(3):736-40

[42] Molostvov G, Fletcher S, Bland R et al. Extracellular calcium-sensing receptor mediated signalling is involved in human vascular smooth muscle cell proliferation and apoptosis. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2008;22(5-6):413-22 (full text)

[43] Mendoza FJ, Martinez-Moreno J, Almaden Y et al. Effect of calcium and the calcimimetic AMG 641 on matrix-Gla protein in vascular smooth muscle cells. Calcified tissue international 2011 Mar;88(3):169-78

[44] Ishimura E, Okuno S, Kitatani K et al. Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clinical nephrology 2007 Oct;68(4):222-7

[45] Montes de Oca A, Guerrero F, Martinez-Moreno JM et al. Magnesium inhibits Wnt/β-catenin activity and reverses the osteogenic transformation of vascular smooth muscle cells. PloS one 2014 Feb 25;9(2):e89525 (full text)

[46] Montezano AC, Zimmerman D, Yusuf H et al. Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. Hypertension (Dallas, Tex. : 1979) 2010 Sep;56(3):453-62 (full text)

[47] Ennever J, Vogel JJ Magnesium inhibition of apatite nucleation by proteolipid. Journal of dental research 1981 Apr;60(4):838-41

[48] Kircelli F, Peter ME, Sevinc Ok E et al. Magnesium reduces calcification in bovine vascular smooth muscle cells in a dose-dependent manner. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association 2012 Feb;27(2):514-21 (full text)

[49] Wajih N, Borras T, Xue W et al. Processing and transport of matrix gamma-carboxyglutamic acid protein and bone morphogenetic protein-2 in cultured human vascular smooth muscle cells: evidence for an uptake mechanism for serum fetuin. The Journal of biological chemistry 2004 Oct 8;279(41):43052-60 (full text)

[50] Ciceri P, Elli F, Brenna I et al. The calcimimetic calindol prevents high phosphate-induced vascular calcification by upregulating matrix GLA protein. Nephron. Experimental nephrology 2012;122(3-4):75-82

[51] Raggi P, Chertow GM, Torres PU et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association 2011 Apr;26(4):1327-39 (full text)

[52] Block GA, Wheeler DC, Persky MS et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology : JASN 2012 Aug;23(8):1407-15 (full text)

[53] Murshed M, Schinke T, McKee MD et al. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. The Journal of cell biology 2004 Jun 7;165(5):625-30 (full text)

Tabella 1
An overview of the interactions between phosphate, calcium, magnesium and MGP

Article Cell line Used ion concentrations Duration MGP detection Result
Julien, 2007
(ref.n. 29)
ATDC5 cell line


Pi unknown control concentration, 10.0 mM

Ca2+ unknown

Mg2+. unknown

24 hours PCR High phosphate increased MGP gene expression
Julien, 2009

(ref.n. 30)

MC3T3-E1 cell line (osteoblast precursor cells)

and primary osteoblasts mice

Pi 1.0, 9.0 mM

Ca2+ unknown

Mg2+. unknown

24 hours PCR and western blotting High phosphate increased MGP gene expression
Louvet L, 2013
(ref. n. 5)
Human aorta VSMC Pi 0.9, 3.0 mM

Ca2+ 1.8 mM

Mg2+. 0.8, 1.5, 2.0 mM

21 days ELISA on cell medium High phosphate increased MGP protein

High magnesiumdecreased MGP protein

Khoshniat, 2011
(ref. n. 31)
MC3T3-E1 cell line (osteoblast precursor cells) Pi 1.0, 10.0 mM

Ca2+ 0, 1.8 mM

Mg2+. unknown

24 hours PCR High phosphate increased MGP gene expression

High calcium increased MGP gene expression

Kapustin, 2011
(ref. n. 32)
Human aorta VSMC Pi 2.5 mM

Ca2+ 5.4, 2.7 mM

Mg2+. unknown

5 days Mass spectrometry on MGP in MV High phosphate did not change MGP protein

High calciumdecreased MGP protein

Farzaneh-Far, 2000
(ref. n. 41)
Rat aorta VSMC Pi unknown

Ca2+ 1.8, 6.0 mM

Mg2+ unknown

48 hours PCR High calciumincreased MGP gene expression
Nakatani, 2006
(ref. n. 40)
ATDC5 cell line (chondrocytes) Pi unknown

Ca2+ 1.0, 6.0 mM

Mg2+ 0.7, 4.2 mM

28 days PCR and immunohistochemistry High phosphate increased MGP protein and gene expression

High magnesiumdecreased MGP protein and gene expression

Montezano, 2010
(ref. n. 46)
VSMC WKY rats and inbred mice Pi unknown

Ca2+ unknown

Mg2+ 2.0, 2.5, 3.0 mM

10 days PCR High magnesiumincreased MGP gene expression
Kircelli F, 2012
(ref. n. 48)
Bovine VSMC Pi 0.9 mM

Ca2+ 1.8 mM

Mg2+ 1.0, 2.0, 3.0 mM

14 days ELISA on cell medium High Magnesiumincreased MGP protein
Montes de OA, 2014
(ref. n. 45)
Human aorta VSMC Pi 0.9, 3.3 mM

Ca2+ 1.8 mM

Mg2+ 0.8, 1.4, 2.6 mM

9 days PCR High Magnesiumincreased MGP gene expression